Home
FHTX
FHTX News

Latest Foghorn Therapeutics Inc. (FHTX) News on July 2, 2025

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

GlobeNewswire

a month ago

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

Zacks

2 months ago

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

GlobeNewswire

2 months ago

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development

PR Newswire

2 months ago

Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

GlobeNewswire

2 months ago

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

GlobeNewswire

2 months ago

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

GlobeNewswire

2 months ago

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

GlobeNewswire

3 months ago

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

GlobeNewswire

3 months ago

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

Zacks

4 months ago

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates

MT Newswires

4 months ago

Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

GlobeNewswire

4 months ago

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses

Simply Wall St.

4 months ago

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Zacks

4 months ago

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire

4 months ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks

5 months ago

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks

TipRanks

5 months ago

Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks

Techne (TECH) Tops Q2 Earnings and Revenue Estimates

Zacks

5 months ago

Techne (TECH) Tops Q2 Earnings and Revenue Estimates

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Zacks

5 months ago

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

MT Newswires

5 months ago

B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target

MT Newswires

5 months ago

Foghorn Therapeutics Files $300 Million Mixed Securities Shelf

Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

6 months ago

Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

6 months ago

Foghorn Therapeutics Outlines Year Ahead for Oncology Drug Candidates

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

GlobeNewswire

6 months ago

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know

Zacks

6 months ago

Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know

Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright

TipRanks

6 months ago

Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright

Foghorn Therapeutics Advances Precision Oncology Pipeline

TipRanks

6 months ago

Foghorn Therapeutics Advances Precision Oncology Pipeline

MT Newswires

7 months ago

Wedbush Cuts Price Target on Foghorn Therapeutics to $10 From $13, Keeps Outperform Rating

MT Newswires

7 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires

7 months ago

Foghorn Therapeutics Discontinues Development of FHD-286 Clinical Program; Shares Fall Pre-Bell

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

GlobeNewswire

7 months ago

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)

Zacks

7 months ago

After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)

Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why

Zacks

7 months ago

Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why

Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?

Zacks

7 months ago

Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire

8 months ago

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report

Simply Wall St.

8 months ago

Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Third-Quarter Report

We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully

Simply Wall St.

8 months ago

We Think Foghorn Therapeutics (NASDAQ:FHTX) Needs To Drive Business Growth Carefully

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Zacks

8 months ago

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

GlobeNewswire

8 months ago

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

PR Newswire

8 months ago

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Foghorn Therapeutics Unveils Clinical Pipeline Progress

TipRanks

9 months ago

Foghorn Therapeutics Unveils Clinical Pipeline Progress

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

GlobeNewswire

9 months ago

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?

Zacks

9 months ago

BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

PR Newswire

9 months ago

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

Foghorn Therapeutics to Participate in the BMO Oncology Summit

GlobeNewswire

9 months ago

Foghorn Therapeutics to Participate in the BMO Oncology Summit

MT Newswires

9 months ago

Foghorn Therapeutics Insider Sold Shares Worth $367,706, According to a Recent SEC Filing

MT Newswires

9 months ago

Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating

Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?

Zacks

10 months ago

Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?

Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ...

GuruFocus.com

10 months ago

Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ...

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

GlobeNewswire

10 months ago

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

MT Newswires

10 months ago

Jefferies Initiates Foghorn Therapeutics at Buy

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet

Zacks

10 months ago

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

GlobeNewswire

10 months ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

Zacks

10 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Zacks

a year ago

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

GlobeNewswire

a year ago

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner

PR Newswire

a year ago

Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner

Institutional investors own a significant stake of 36% in Foghorn Therapeutics Inc. (NASDAQ:FHTX)

Simply Wall St.

a year ago

Institutional investors own a significant stake of 36% in Foghorn Therapeutics Inc. (NASDAQ:FHTX)

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

**Canadian Interest in American Whiskey Peaks Ahead of Bourbon Day**

CNW Group

a year ago

Canadian Interest in American Whiskey Peaks Ahead of Bourbon Day

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Where Will DocuSign Stock Be in 1 Year?

Motley Fool

a year ago

Where Will DocuSign Stock Be in 1 Year?

Spotify to introduce expensive plan later this year, Bloomberg News reports

Reuters

a year ago

Spotify to introduce expensive plan later this year, Bloomberg News reports

Poppulo Joins Elite Category in BrightSign Bright Alliance Program, Announces Certification Across Series 5 Devices

GlobeNewswire

a year ago

Poppulo Joins Elite Category in BrightSign Bright Alliance Program, Announces Certification Across Series 5 Devices

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

GlobeNewswire

a year ago

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

GlobeNewswire

a year ago

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

MT Newswires

a year ago

Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

a year ago

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Simply Wall St.

a year ago

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...

GuruFocus.com

a year ago

Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

Zacks

a year ago

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

GlobeNewswire

a year ago

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

GlobeNewswire

a year ago

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

GlobeNewswire

a year ago

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

GlobeNewswire

a year ago

Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?

Zacks

a year ago

Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

GlobeNewswire

a year ago

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know

Zacks

a year ago

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know

Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know

Zacks

a year ago

Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

Zacks

a year ago

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

GlobeNewswire

a year ago

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

GlobeNewswire

a year ago

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?

Zacks

a year ago

Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?

Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

GlobeNewswire

a year ago

Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

Zacks

a year ago

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

Zacks

a year ago

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

GlobeNewswire

a year ago

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

Morningstar Research

a year ago

Analyst Report: SunPower Corporation

SunPower Provides Update on Discussions with Key Financial Partners

PR Newswire

a year ago

SunPower Provides Update on Discussions with Key Financial Partners

Best Income Stocks to Buy for February 1st

Zacks

a year ago

Best Income Stocks to Buy for February 1st

Mama’s Creations to Host Virtual Investor Day Presentation on Tuesday, February 13, 2024

GlobeNewswire

a year ago

Mama’s Creations to Host Virtual Investor Day Presentation on Tuesday, February 13, 2024

Tactile Medical to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 20, 2024

GlobeNewswire

a year ago

Tactile Medical to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 20, 2024

18 Best 52-Week Low Stocks To Buy Now

Insider Monkey

a year ago

18 Best 52-Week Low Stocks To Buy Now

BCB Bancorp, Inc. (NASDAQ:BCBP) most popular amongst retail investors who own 51% of the shares, institutions hold 36%

Simply Wall St.

a year ago

BCB Bancorp, Inc. (NASDAQ:BCBP) most popular amongst retail investors who own 51% of the shares, institutions hold 36%

Share on Social Networks: